"AMS [is] an invaluable tool in our early drug development program, allowing us to quickly assess bioavailability in humans and focus resources on our most promising drug candidates going forward."- Speedel
"Xceleron have pioneered the human Phase 0 Microdose approach [enabling] us to see the potential utility of AMS in improving our drug selection procedures."- Servier
"A pioneer of biomedical applications of AMS , Xceleron has developed specific expertise in this ultra-sensitive analytical technique."- GSK
"By working with Xceleron, we hope to obtain an early read of human drug metabolites instead of relying on animal models."- Otsuka Pharmaceutical Development and Commercialization
"The most compelling reason for using human microdosing is the speed with which we can gain results from human studies to make pivotal decisions."- Organon
"We are gaining important information that has not been available to us previously"- Sanofi Aventis
  • Latest News

    Pharmaron Acquires Majority Stake in SNBL CPC

    Read more »

  • What our clients are saying about us...

    "...AMS [is] an invaluable tool in our early drug development program, allowing us to quickly assess bioavailability in humans and focus resources on our most promising drug candidates going forward."

    See more client quotes »

  • Get Phase II Ready

    Find out how we can help you accelerate your drug-development program.

    Email us now »

© Xceleron 2017 All Rights Reserved.